Company Name: |
J & K SCIENTIFIC LTD.
|
Tel: |
010-82848833 400-666-7788 |
Email: |
jkinfo@jkchemical.com |
Products Intro: |
Product Name:Plerixafor CAS:1246819-87-3 Package:2.5Mg,25Mg
|
Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
Tel: |
18818260767 |
Email: |
sales@chemegen.com |
Products Intro: |
Product Name:Plerixafor-d4 CAS:1246819-87-3 Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
|
| Plerixafor Basic information |
| Plerixafor Chemical Properties |
Melting point | 100-102°C | storage temp. | Hygroscopic, Refrigerator, Under Inert Atmosphere | solubility | DMSO (Slightly, Heated, Sonicated), Methanol (Slightly), Water (Slightly) | form | Solid | color | White to Light Yellow | Stability: | Very Hygroscopic |
| Plerixafor Usage And Synthesis |
Description | Plerixafor-d4 is intended for use as an internal standard for the quantification of plerixafor by GC- or LC-MS. Plerixafor is a partial antagonist of chemokine receptor 4 (CXCR4) with IC50 values ranging from 0.02 to 0.13 μg/ml for inhibiting calcium flux in peripheral blood mononuclear cells (PBMCs), various types of T cells, and mouse lymphocytic leukemia cells. It is selective for CXCR4 over CXCR1-3 and CXCR5-9 (IC50s = >25 μg/ml). Plerixafor decreases infectious virus content in the supernatant of Jurkat cells chronically infected with HIV-1(IIIB) (EC50 = ~0.02 μg/ml). It rapidly mobilizes murine and human hematopoietic stem and murine long-term repopulating cells for transplantation alone and, with a synergistic effect, when used in combination with G-CSF. Plerixafor also increases T cell trafficking in mouse blood, spleen, and central nervous system. Plerixafor (1.25 mg/kg twice per day) decreases the number of 4T1 murine mammary carcinoma cells in the lung in a mouse model of lung metastasis. | Chemical Properties | Off-White Solid | Uses | Labelled Plerixafor, it is a hematopoietic stem cell (HSC) mobilizer that inhibits the CXCR4 chemokine receptor and blocks binding of its ligand, stromal cell-derived factor-1-α (SDF-1-α). This agent was approved on Dec. 15, 2008, as treatment in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin''s lymphoma (NHL) and multiple myeloma (MM). |
| Plerixafor Preparation Products And Raw materials |
|